论文信息 - A case of secondary diabetes mellitus with acromegaly improved by pioglitazone

A case of secondary diabetes mellitus with acromegaly improved by pioglitazone

Aim The acromegaly patient was diagnosed with Type 2 diabetes mellitus. His HbA1c was 10.6% and fasting blood glucase (FBG) 15.3 mmol/l. We prescribed glibenclamide (10 mg/day), but his HbA1c and FBG remained high. At this stage, treatmer with short‐acting insulin was instigated at a dose of 20 U/day. However, the patient's blood glucose level remained unsatisfactory. We tried using pioglitazone.

[1] M. Matsuda,et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. , 2001, Diabetes care.

[2] J. Petrie. Pioglitazone: A Viewpoint by John R. Petrie , 2000 .

[3] A. Melander,et al. Thiazolidinediones for type 2 diabetes , 2000, BMJ : British Medical Journal.

[4] J. Petrie,et al. Pioglitazone : A viewpoint , 2000 .

[5] B. Spiegelman. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[6] D. McClain,et al. Hexosamines and Insulin Resistance , 1996, Diabetes.

[7] B. Spiegelman,et al. IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance , 1996, Science.

[8] J. Olefsky,et al. Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects , 1992, Diabetes Care.